Cargando…

Molecular Interplay between AURKA and SPOP Dictates CRPC Pathogenesis via Androgen Receptor

SIMPLE SUMMARY: Prostate cancer is the most common type of cancer in men. Early stage prostate cancer is treatable. However, remission eventually occurs in vast majority of patients, giving rise to castration-resistant prostate cancer (CRPC), which is incurable with current therapies. Aurora A (AURK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nikhil, Kumar, Kamra, Mohini, Raza, Asif, Haymour, Hanan S., Shah, Kavita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693105/ https://www.ncbi.nlm.nih.gov/pubmed/33158056 http://dx.doi.org/10.3390/cancers12113247

Ejemplares similares

Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer
por: Nikhil, Kumar, et al.
Publicado: (2020)

Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models
por: Sooreshjani, Moloud Aflaki, et al.
Publicado: (2021)

Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer
por: Bernasocchi, Tiziano, et al.
Publicado: (2021)

Aurora Kinase A-YBX1 Synergy Fuels Aggressive Oncogenic Phenotypes and Chemoresistance in Castration-Resistant Prostate Cancer
por: Nikhil, Kumar, et al.
Publicado: (2020)

Intrinsically disordered substrates dictate SPOP subnuclear localization and ubiquitination activity
por: Usher, Emery T., et al.
Publicado: (2021)

The expression of AURKA is androgen regulated in castration-resistant prostate cancer
por: Kivinummi, Kati, et al.
Publicado: (2017)

SPOP the mutation
por: Rider, Leah, et al.
Publicado: (2015)

LIMK2-NKX3.1 Engagement Promotes Castration-Resistant Prostate Cancer
por: Sooreshjani, Moloud A., et al.
Publicado: (2021)

Evaluation of the Association between Androgen Receptor and AURKA and Its Prognostic Value in Gastric Cancer
por: Soleymani Fard, Shahrzad, et al.
Publicado: (2019)

SUN-003 Targeting Androgen Receptor-CXCR7-MARK Signaling Axis in CRPC
por: Gritsina, Galina, et al.
Publicado: (2019)

Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate-Cancer-Associated Mutants
por: An, Jian, et al.
Publicado: (2014)

Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide
por: Hong, Zhe, et al.
Publicado: (2021)

The establishment of an immunosensor for the detection of SPOP
por: Yue, Song, et al.
Publicado: (2021)

Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells
por: Yang, Yan, et al.
Publicado: (2020)

Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Ryan, Charles J, et al.
Publicado: (2019)

AURKA inhibition mimics BRCAness
por: Hirst, Jeff, et al.
Publicado: (2017)

Molecular interplay between linc01134 and YY1 dictates hepatocellular carcinoma progression
por: Rong, Zhonghou, et al.
Publicado: (2020)

Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy
por: Du, Ruijuan, et al.
Publicado: (2021)

Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP–HIPK2 axis
por: Jin, Xiaofeng, et al.
Publicado: (2021)

Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype
por: Robinson, Jessica L.L., et al.
Publicado: (2013)

AURKA, TOP2A and MELK are the key genes identified by WGCNA for the pathogenesis of lung adenocarcinoma
por: Xu, Yunqing, et al.
Publicado: (2023)

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC
por: Sena, Laura A., et al.
Publicado: (2022)

SPOP loss of function protects against tauopathy
por: Eck, Randall J., et al.
Publicado: (2022)

Integrated pan‐cancer of AURKA expression and drug sensitivity analysis reveals increased expression of AURKA is responsible for drug resistance
por: Miralaei, Noushin, et al.
Publicado: (2021)

SPOP mutation leads to genomic instability in prostate cancer
por: Boysen, Gunther, et al.
Publicado: (2015)

Identification of SPOP related metabolic pathways in prostate cancer
por: Yan, Min, et al.
Publicado: (2017)

The Roles of SPOP in DNA Damage Response and DNA Replication
por: Maekawa, Masashi, et al.
Publicado: (2020)

The emerging role of SPOP protein in tumorigenesis and cancer therapy
por: Song, Yizuo, et al.
Publicado: (2020)

SPOP Inhibition of Endometrial Carcinoma and Its Clinicopathological Relationship
por: Zhu, Qing, et al.
Publicado: (2022)

Systematically understanding the immunity leading to CRPC progression
por: Ji, Zhiwei, et al.
Publicado: (2019)

Increased expression of CYP17A1 indicates an effective targeting of the androgen receptor axis in castration resistant prostate cancer (CRPC)
por: Bremmer, Felix, et al.
Publicado: (2014)

Metabolic Variation Dictates Cardiac Pathogenesis in Patients With Tetralogy of Fallot
por: Liu, Jianyang, et al.
Publicado: (2022)

SPOP suppresses pancreatic cancer progression by promoting the degradation of NANOG
por: Tan, Peng, et al.
Publicado: (2019)

Association of SPOP Expression with the Immune Response to Salmonella Infection in Chickens
por: Wang, Fei, et al.
Publicado: (2020)

SPOP in Cancer: Phenomena, Mechanisms and Its Role in Therapeutic Implications
por: Yang, Xiaojuan, et al.
Publicado: (2022)

Retracted: SPOP Inhibition of Endometrial Carcinoma and Its Clinicopathological Relationship
por: and Biomechanics, Applied Bionics
Publicado: (2023)

Clinical response in metastatic castration‐resistant prostate cancer (mCRPC) cases treated with supra‐physiological doses of testosterone: Bipolar androgen therapy
por: Hoshi, Senji, et al.
Publicado: (2022)

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide
por: Del Re, M., et al.
Publicado: (2021)

mCRPC Patients Receiving (225)Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis
por: Sathekge, Mike, et al.
Publicado: (2022)

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_areb9suoqdkcpfkmaf6eo8pfju